Novartis AG

Suisse


 
Quantité totale PI 11 063
Quantité totale incluant filiales 19 647 (+ 8 800 pour les filiales)
Rang # Quantité totale PI 79
Note d'activité PI 4,3/5.0    4 822
Rang # Activité PI 116
Activité incl filiales 4,3/5.0    8 512
Symbole boursier
ISIN CH0012005267
Capitalisation 178.7B  (CHF)
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

1 843 1 256
580 826
3 487 2 074
997
 
Dernier brevet 2025 - Fap targeting cyclic peptides an...
Premier brevet 1973 - O-substituted 7.beta.-amino-3-ce...
Dernière marque 2025 - QYNETRU
Première marque 1942 - METHERGINE

Filiales

124 subsidiaries with IP (5947 patents, 2853 trademarks)

78 subsidiaries without IP

 S'inscrire grtuitement pour accéder à la liste des filiales

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 P/S Pharmaceutical preparations.
P/S Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal prep...
P/S providing an internet website portal offering the sale of products in the field of health and med...
2024 Invention Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide poly...
P/S Logiciels téléchargeables pour la fourniture d'informations médicales et pharmaceutiques aux pati...
P/S Downloadable software for use in providing medical and pharmaceutical information for patients; d...
P/S Downloadable software for use in providing medical and pharmaceutical information for patients; ...
P/S Dietary and nutritional supplements; vitamins.
Invention Means and method for preparing viral vectors and uses of same. Methods for preparing and purifyi...
P/S Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à sa...
P/S Services de conseils en affaires dans le domaine de la mise en place, de la pratique et du foncti...
P/S Business consulting services in the field involving the implementation, practice and operation of...
P/S Business consulting services in the field involving the implementation, practice and operation o...
P/S Business consulting services in the field of set-up, practice and operation of radioligand imagi...
P/S Business consulting services in the field of set-up, practice and operation of radioligand imagin...
Invention Antibody drug conjugates for ablating hematopoietic stem cells. The present invention provides a...
P/S Providing a web site featuring medical information; providing medical information in the field of...
Invention Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof. The present...
Invention S1p modulator immediate release dosage regimen. The present invention relates to siponimod (BAB3...
Invention Nlrp3 inflammasome inhibitors. The present invention relates to novel pyridazin-3-yl phenol comp...
Invention Dosage regimens for anti-pd-l1 antibodies and uses thereof. Antibody molecules that specifically...
Invention 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof. The present di...
Invention Methods of using factor b inhibitors. Described herein are methods of treating gMG (generalized M...
Invention Fap targeting cyclic peptides and conjugates thereof. Described herein are cyclic peptides targe...
Invention Immunosuppressant formulations. The present invention relates to a solid phase pharmaceutical co...
Invention Fap targeting cyclic peptides and conjugates thereof. Described herein are cyclic peptides target...
Invention Compounds and compositions for modulating the activity of erk. The invention relates to compound...
Invention Compounds and compositions for modulating the activity of erk. The invention relates to compounds...
Invention Selective reduction of cysteine residues in il-17 antibodies. The present disclosure relates to ...
Invention Antiviral 1,3-di-oxo-indene compounds. This disclosure provides compounds of Formula (I) This ...
Invention Compositions and methods of use for therapeutic antibodies. The present invention relates to ant...
Invention Human mesothelin chimeric antigen receptors and uses thereof. Provided are compositions and meth...
Invention New uses of omalizumab. 150mg/mL omalizumab formulation for use in a method of treatment of one o...
Invention Polyomavirus neutralizing antibodies. The present invention relates to anti-VP1 antibodies, anti...
Invention Psma-targeting radioligand treatment regimen. Described herein are radiopharmaceuticals for the t...
Invention Method of treating prostate cancer. The present disclosure relates to a method of treating prosta...
Invention Sodium channel blockers. The present disclosure relates to sulfonamide compounds, the use thereo...
Invention Sodium channel blockers. The present disclosure relates to sulfonamide compounds, the use thereof...
Invention 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridaz...
Invention Anti-ige antibody therapy for multiple food allergies. The present disclosure provides methods a...
Invention Method and apparatus for using omalizumab. A method of treating a patient with of one or more of...
Invention Combination. A novel combination comprising a 17 α-hydroxylase/C17,20 lyase inhibitor, for examp...
Invention Antibody molecules to pd-1 and uses thereof. Antibody molecules that specifically bind to PD-1 a...
Invention Digital solutions for differentiating asthma from copd. The present disclosure relates generally...
Invention Il-18 binding molecules. IL-18 participates in both innate and acquired immunity. The bioactivit...
Invention Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagon...
Invention Immunosuppressant formulation. The present invention concerns a dosage form, preferably for imme...
Invention Methods of using factor b inhibitors. Described herein are methods of treating paroxysmal noctur...
Invention Heteroaromatic nmda receptor modulators and uses thereof. Provided is 5-(3-chloro-4-fluorophenyl...
Invention Ribociclib tablet. The present disclosure is directed to oral tablet of ribociclib including its...
2023 Invention Methods of treating chronic spontaneous urticaria using ligelizumab. The present disclosure rela...
Invention Tetrahydro-pyrido-pyrimidine derivatives. The invention relates to substituted tetrahydro-pyrido...
Invention Stable and soluble antibodies inhibiting vegf. The present invention relates to soluble and stab...
Invention Tlr7/8-antagonist for treating sjögren's syndrome or mixed connective tissue disease. The presen...
2022 Invention Pyridine-3-carboxylate compounds as cav1.2 activators. The present disclosure provides for a com...
Invention Methods of treatment using lou064. The present disclosure relates to methods of treating and/or ...
Invention Staggered triple lipid-modified nucleic acid compounds. Disclosed herein are compounds including...
Invention Methods for determining the biological activity of angptl polypeptides. Provided herein are meth...
Invention Engineered fc variants. The present invention describes engineered immunoglobulin IgG Fc regions...
Invention Crystalline forms of biaryl yap/taz-tead protein-protein interaction inhibitors. The present inv...
Invention Compounds and compositions for the treatment of coronaviral related diseases. Provided herein ar...
Invention Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis. The present disclosure...
2019 Invention Novel dosing regimens for mdm2 inhibitors. The present invention relates to the HDM2-p53 interac...